Male, 5-week-old BALB/c-nu/nu mice (CAnN. Cg-Foxn1/CrlCrlj nu/nu) were obtained from Charles River Laboratories Inc. (Kanagawa, Japan). All animals were allowed to acclimatize and recover from shipping-related stress for at least 1 week prior to the study. The health of the mice was monitored by daily observation. The animals were kept under a controlled light-dark cycle (12–12 h), and chlorinated water and irradiated food were provided ad libitum. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee at Chugai Pharmaceutical Co., Ltd.
Balb c nu nu mice cann cg foxn1 crlcrlj nu nu
Manufactured by Charles River Laboratories
Sourced in Japan
BALB/c-nu/nu mice (CAnN. Cg-Foxn1/CrlCrlj nu/nu) are a strain of laboratory mice with a spontaneous mutation in the Foxn1 gene, resulting in a nude phenotype with absence of a functional thymus and lack of mature T cells. These mice are commonly used in research applications that require an immunodeficient animal model.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using balb c nu nu mice cann cg foxn1 crlcrlj nu nu
1
Acclimation and Maintenance of BALB/c-nu/nu Mice
2
Evaluating Erlotinib and Bevacizumab Combination
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Male, 5-week-old BALB/c-nu/nu mice (CAnN.Cg-Foxn1 /CrlCrlj nu/nu) were obtained from Charles River Laboratories Japan (Kanagawa, Japan). Tumours were implanted by subcutaneous injection of B901L cells (5 × 106 cells) into the mice. Tumours in the mice were grown for 14 to 18 days before receiving any treatment. The tumour-bearing mice underwent one of two treatment regimens (Table 1 ): a single dose of erlotinib (60 mg/kg) 5 days after a single dose of bevacizumab (5 mg/kg) (n = 15) or after a single dose of human IgG (5 mg/kg) as control (n = 15), or erlotinib (60 mg/kg) daily for 2 days (n = 5) or for 37 days (n = 5). Erlotinib was administered orally and bevacizumab was administered intraperitoneally. All animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee at Chugai Pharmaceutical Co., Ltd., in accordance with the guidelines.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!